Filing Details

Accession Number:
0001209191-15-005906
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-01-22 17:53:08
Reporting Period:
2015-01-20
Filing Date:
2015-01-22
Accepted Time:
2015-01-22 17:53:08
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1373707 Tetraphase Pharmaceuticals Inc TTPH Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1296998 Guy Macdonald 480 Arsenal St. Suite 110
Watertown MA 02472
President And Chief Executive Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-01-20 10,000 $7.94 60,000 No 4 M Direct
Common Stock Acquisiton 2015-01-20 849 $0.87 60,849 No 4 M Direct
Common Stock Acquisiton 2015-01-20 22,030 $2.03 82,879 No 4 M Direct
Common Stock Acquisiton 2015-01-20 1,256 $5.80 84,135 No 4 M Direct
Common Stock Disposition 2015-01-20 34,135 $36.59 50,000 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (right to buy) Disposition 2015-01-20 10,000 $0.00 10,000 $7.94
Common Stock Employee Stock Option (right to buy) Disposition 2015-01-20 849 $0.00 849 $0.87
Common Stock Employee Stock Option (right to buy) Disposition 2015-01-20 22,030 $0.00 22,030 $2.03
Common Stock Employee Stock Option (right to buy) Disposition 2015-01-20 1,256 $0.00 1,256 $5.80
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
260,000 2023-05-14 No 4 M Direct
109,323 2019-09-10 No 4 M Direct
57,331 2020-09-27 No 4 M Direct
25,834 2018-08-07 No 4 M Direct
Footnotes
  1. The exercise and sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 25, 2014.
  2. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $35.79 to $38.095 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
  3. Vested as to 25% of the original number of shares granted on 5/15/2014 and further vests as to an additional 6.25% of the original number of shares granted at the end of each successive three-month period thereafter until 5/15/2017.
  4. Fully vested.
  5. The number of derivative securities beneficially owned following the transaction reported on this Form 4 has been adjusted to reflect the additional 25,834 incentive stock options owned by the reporting person, and previously reported as a separate option owned by the reporting person, in addition to the non-qualified stock options that were previously reported in the Form 4 filed by the reporting person.